logo
  

Blackstone Group Reportedly Nears Deal To Take Minority Stake In NCR

Blackstone Group LP (BX) is nearing a deal to invest more than $800 million into ATM and cash dispenser maker NCR Corp. (NCR), the Wall Street Journal reported citing people familiar with the matter.

The private-equity firm now plans to announce a deal as soon as Thursday to make the minority equity investment in NCR. NCR also plans to announce a $1 billion share buyback, the report said.

Blackstone is expected to receive convertible preferred shares that pay a dividend and two board seats in exchange for the investment.

According to report, the New York buyout firm will end up with an ownership stake in NCR exceeding 15%. The preferred shares are convertible to regular stock at $30.

It is possible that the deal could fall apart at the last minute.

NCR closed Wednesday trading at $26.78, up $0.07 or 0.26%. In after hours, the stock further gained up $0.73 or 2.73%.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT